Paper Details
- Home
- Paper Details
Drug Regimen Individualization for Attention-Deficit/Hyperactivity Disorder: Guidance for Methylphenidate and Dexmethylphenidate Formulations.
Author: KollerLauren, NguyenLinda V, PatrickKennerly Sexton, RadkeJennifer L, RaymondJohn R, RodriguezWendy, StraughnArthur B
Original Abstract of the Article :
In 2000, the first biphasic modified-release (MR) formulation of methylphenidate (MPH) was approved for the treatment of attention-deficit/hyperactivity disorder (ADHD). An immediate-release (IR) MPH pulse (22% of the dose) facilitates rapid onset of stimulant action, while the remaining MR portion ...See full text at original site
Dr.Camel's Paper Summary Blogラクダ博士について
ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。
* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。
引用元:
https://doi.org/10.1002/phar.2190
データ提供:米国国立医学図書館(NLM)
Understanding Drug Regimen Individualization for Attention-Deficit/Hyperactivity Disorder
This research delves into the diverse array of methylphenidate (MPH) and dexmethylphenidate (dexMPH) formulations available for treating attention-deficit/hyperactivity disorder (ADHD). The study examines the various release profiles and pharmacokinetic characteristics of different MPH and dexMPH products, highlighting the importance of individualized treatment regimens based on patient needs and responses. The authors provide a comprehensive overview of each formulation, enabling clinicians to make informed decisions about optimal drug selection and dosage adjustments.Tailoring Treatment for ADHD with Methylphenidate and Dexmethylphenidate Formulations
This research emphasizes the need for individualized treatment approaches for ADHD, considering the wide variety of available MPH and dexMPH formulations. The study's findings provide valuable insights into the different release profiles and pharmacokinetic characteristics of these medications, allowing clinicians to select the most appropriate formulation for each patient.Choosing the Right Medication for ADHD: A Personalized Approach
This research underscores the importance of personalized medication management for ADHD. The study's findings suggest that careful consideration of different MPH and dexMPH formulations, their pharmacokinetic profiles, and individual patient characteristics can lead to more effective and safe treatment outcomes. Consult with your physician to discuss appropriate medication choices for managing your ADHD symptoms.Dr. Camel's Conclusion
This research reminds me of the diverse tapestry of human experiences, where each individual responds uniquely to medications. Just as the desert landscape features a myriad of plant species, each with its own growth pattern, ADHD patients respond differently to various MPH and dexMPH formulations. This study encourages us to embrace a personalized approach to medication management, tailoring treatment to individual needs and optimizing therapeutic outcomes.Date :
- Date Completed 2020-05-01
- Date Revised 2020-05-01
Further Info :
Related Literature
Article Analysis
SNS
PICO Info
in preparation
Languages
English
Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.